Intelligent Bio Solutions Submits FDA 510(k) for Fingerprint Drug Screening System
INBS sits 47% above its 52-week low of $1.52.
Summary
Intelligent Bio Solutions has submitted its 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System, targeting codeine detection. This is the culmination of a multi-study clinical program completed throughout 2026, including method comparison, usability, interference, precision, and cut-off studies. The submission package includes data showing accuracy above 98%, sensitivity above 94%, and 100% specificity. FDA clearance would open the multi-billion-dollar U.S. drug screening market, expanding the company's addressable market beyond forensic use. The company has a going concern warning and recently raised $5 million in a private placement, so regulatory approval is critical for its commercialization strategy. The FDA's decision timeline is not specified, but acceptance of the submission is the next milestone.
At the time of this announcement, INBS was trading at $2.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5M. The 52-week trading range was $1.52 to $24.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.